FindTrial
Sign In

Immunotherapy for KRAS Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis

Immunotherapy for KRAS Mutant Advanced Non-Small Cell Lung Cancer: A Systematic Review and Network Meta-analysis - Immunotherapy for KRAS Mutant Advanced Non-Small Cell Lung Cancer

Status
Recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000052814
Enrollment
Unknown
Registered
2023-11-16
Start date
2023-11-16
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced non-small cell lung cancer

Interventions

None listed

Sponsors

National Center for Global Health and Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Phase III trials investigating the efficacy of immune checkpoint inhibitors as monotherapy or in combination with platinum agents for advanced Non-Small Cell Lung Cancer, with accessible KRAS mutation Information

Exclusion criteria

Exclusion criteria: Excluded from the analysis were phase 1/phase 2 trials, single-arm trials, observational studies, and meta-analyses. Studies lacking information on KRAS mutations were also excluded.

Design outcomes

Primary

MeasureTime frame
overall survival—

Secondary

MeasureTime frame
Progression Free Survival—

Countries

Japan

Contacts

Public ContactAkinari Tsukada

National Center for Global Health and Medicine Department of Respiratory Medicine

atsukada@hosp.ncgm.go.jp+81-3-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026